

Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors, a FCCSS Study

Thibaud Charrier, Brice Fresneau, Nadia Haddy, Boris Schwartz, Neige Journy, Charlotte Demoor-Goldschmidt, Ibrahima Diallo, Aurore Surun, Isabelle Aerts, François Doz, et al.

▶ To cite this version:

Thibaud Charrier, Brice Fresneau, Nadia Haddy, Boris Schwartz, Neige Journy, et al.. Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors, a FCCSS Study. RADRES, Oct 2022, Waikoloa, United States. hal-04488310

HAL Id: hal-04488310 https://hal.science/hal-04488310v1

Submitted on 4 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors, a FCCSS Study

Thibaud Charrier, Rodrigue S. Allodji, Aurélien Latouche, Florent de Vathaire, et al.




BACKGROUND

Advances in cancer treatment have significantly improved childhood cancer survival, with five-year survival exceeding 80% in most European and North American countries today. The adult population of childhood cancer survivors (CCS) exceeds 300,000 people in the USA alone, and is growing. Many late-effects have been observed at a higher rate than the general population.

Cardiac disease (CD) and second malignant neoplasms (SMN) are among the most serious and life-threatening late adverse effects experienced by CCS.

Previous work has identified important risk factors of CD, but the impact of other late-effects as SMN have been ignored.

We have studied the effect of a SMN on both the cumulative incidence and the instantaneous risk of CD accounting for the competing risk of death.



METHODS

Population: Analysis included 7670 CCS diagnosed between 1945 and 2000, treated with combinations of surgery, radiotherapy (RT) and chemotherapy (CT).


Cumulative Incidence: To account for the time dependance of the occurrence of SMN, we employed the landmark approach considering an additive regression model for the cumulative incidence of CVD.

Instantaneous Risk: Next, the effect of SMN on the instantaneous risk of CVD was estimated using a proportional cause specific hazard model considering SMN as a time-dependent exposure.

Shared technique: In both models, we included death as a competing event, and adjusted for childhood cancer treatment information (age at diagnosis, radiotherapy doses, anthracyclines, ...).

CUMULATIVE INCIDENCE OF CD

ADDITIVE EFFECT OF SMN ON



RESULTS

- ♦ Overall, after a median follow-up of 29 years, 470 CVDs including 63 experimenting a SMN were identified.
- ◆ An increased cumulative incidence of CVD was estimated for patients experimenting a SMN before they reached 35 years old.
- ◆ This increase was of 4.8% [95%CI: 1.0-8.6%] at 30 years old, with a cumulative incidence of 6%.
- ◆ No increase in the cumulative incidence of CVD was observed for later landmark times.
- ◆ SMN has been estimated to multiply the cause-specific-hazard by a 2.2 fold [95% CI: 1.6-3.0].

CONCLUSION

- SMN occurrence does increase instantaneous risk of CD at all age.
- SMN occurrence before 35 years old does increase the cumulative incidence of CD.
- X Our results provide new insight into the CVD risk after a SMN that may impact long-term follow-up of CCS.











